Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Long-Term Extension Study for Oral Levosimendan (TNX-103)

NCT07436689 is registered in ClinicalTrials.gov with Tenax Therapeutics, Inc. as lead sponsor.

NCT NCT07436689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07436689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Long-Term Extension Study for Oral Levosimendan (TNX-103)
Lead sponsor
Tenax Therapeutics, Inc.
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
March 13, 2026
Completion date
March 31, 2029
Enrollment
800 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension associated with hfpef